Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

This was the stock's second consecutive day of losses.

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Barclays has recently reduced Vertex Pharmaceuticals Incorporated (VRTX) stock to Equal Weight rating, as announced on August 5, 2024, according to Finviz. Earlier, on June 27, 2024, Redburn Atlantic ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

Joining us this morning at our Cantor Global Healthcare Conference. Really excited to have another year of it. My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really ...